Sudden discontinuation and reinstitution of olanzapine-associated atypical neuroleptic malignant syndrome in a patient undergoing lung surgery

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 7, 2015, Pages 11639-11641

  Zhao, Zhiyong ^a   Zhang, Hua ^b   Wang, Shaohua ^a   Chen, Xiaofeng ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

Atypical neuroleptics; Neuroleptic malignant syndrome; Perioperative period

Indexed keywords

AMBROXOL; BROMOCRIPTINE; BUDESONIDE; CEFUROXIME; CLOZAPINE; CREATINE KINASE; DANTROLENE; DOPAMINE RECEPTOR; LANSOPRAZOLE; OLANZAPINE; PROPACETAMOL; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CONFUSION; CONSCIOUSNESS DISORDER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; HIGH RISK PATIENT; HUMAN; HYPERTHERMIA; LEUKOCYTOSIS; LUNG NODULE; LUNG SURGERY; MALE; MENTAL DISEASE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PERIOPERATIVE PERIOD; SCHIZOPHRENIA;

EID: 84940702591     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Woo BK and Obrocea GV. Atypical case of neuroleptic malignant syndrome caused by olanzapine and carbamazepine. Psychiatry (Edgmont) 2005; 2: 23-24.
2. Hickey CC Stewart and S. Lippmann, Olan-Zapine and NMS. Psychiatr Serv 1999; 50: 836-837.
3. Hanel RA, Sandmann MC, Kranich M, De Bittencourt PR. [Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine]. Arq Neuropsiquiatr 1998; 56: 833-837.
4. Lieberman AP. Pasternack P and Colvin S. The neuroleptic malignant syndrome after open heart surgery: successful treatment with bromocriptine. N Y State J Med 1987; 87: 362-363.
5. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137-1145.
6. Trull TJ, Vergés A, Wood PK, Jahng S, Sher KJ. The structure of Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision) personality disorder symptoms in a large national sample. Personal Disord 2012; 3: 355-369.
7. Strawn JR, Keck PJ and Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164: 870-876.
8. Tsuchiya N, Morimura E, Hanafusa T, Shino-mura T. Postoperative neuroleptic malignant syndrome that occurred repeatedly in a patient with cerebral palsy. Paediatr Anaesth 2007; 17: 281-284.
9. Patel P and Bristow G. Postoperative neuroleptic malignant syndrome. A case report. Can J Anaesth 1987; 34: 515-518.
10. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54: 49-55.
11. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry 1989; 46: 914-918.
12. Patra BN, Khandelwal SK and Sood M. Olanzapine induced neuroleptic malignant syndrome. Indian J Pharmacol 2013; 45: 98-99.